BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

As a stellar drug for hereditary angioedema, BioCryst Pharmaceuticals' Orladeyo is enjoying strong sales reactions in its second year of launch. Coupled with ongoing global market expansions and on top of its efficacy, Orledayo is poised to become a blockbuster in the next few years.

BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

BioCryst Pharmaceuticals (NASDAQ: BCRX ) stock is falling on Thursday after revealing the end of development for BCX9930. BCX9930 was in development alongside BCX10013 as a Factor D inhibitor.

BCRX Stock Sinks as BioCryst Discontinues Drug Development

Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysmal nocturnal hemoglobinuria and some renal diseases, saying it no longer believes the therapeutic candidate is competitive commercially. BioCryst told investors that discontinuing the BCX9930 program will have a positive financial impact, and research and development expenses in 2023 will be similar to 2022's figures.

BioCryst to discontinue development of drug

RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX9930 would be commercially competitive, and is discontinuing the development of BCX9930. This decision allows the company to fully focus its complement inhibitor development efforts on BCX10013, a potential once-daily, oral Factor D (alternative pathway) inhibitor currently in clinical development, and pursue additional oral compounds for multiple targets across other complement pathways.

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET.

BioCryst to Present at JMP Securities Hematology & Oncology Summit

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

Cerus

Eyenovia

Here are three inexpensive biotech stocks with a bright future ahead of them.

3 Biotechnology stocks under 10 dollars to buy now

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE), including patients who switched from other prophylactic therapies.

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Ken Cacciatore - Cowen and Company Chris Raymond - Piper Sandler Daniel Wolle - JPMorgan Joe Spak - RBC Capital Jon Wolleben - JMP Securities Gena Wang - Barclays Justin Kim - Oppenheimer & Company Tazeen Ahmad - Bank of America Rohit Bhasin - Needham & Company Maury Raycroft - Jefferies Operator Hello, and welcome to the BioCryst Third Quarter 2022 Earnings Conference Call. My name is Michelle and I will be your operator for today's conference.

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript

—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021—

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

Alnylam Pharmaceuticals

Amgen

Beam Therapeutics

CRISPR Therapeutics

Graphite Bio

Ionis Pharma

Intellia Therapeutics

Pfizer

Regeneron Pharmaceuticals

Takeda Pharmaceutical

Verve Therapeutics

Vertex Pharmaceuticals

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results Tuesday, November 1, 2022.

BioCryst to Report Third Quarter 2022 Financial Results on November 1

STERIS

BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.

Got $3,000? Here Are 2 Stocks That Will Make You Richer

Exelixis

Vir Biotechnology

Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 21% over the past three months compared with a 6% gain for the S&P 500.

3 Biotech Stocks to Buy Now for Extraordinary Gains

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company's significant pipeline of development candidates. Dr. Ryan Arnold has been appointed as the company's new chief medical officer.

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Study represents first data with BCX9930 in C3G patients Study represents first data with BCX9930 in C3G patients

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst's antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Saudi Arabia.

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is soaring today, last seen up 22.5% at $13.65, after the drug maker said the U.S. Food and Drug Administration (FDA) lifted a partial clinic hold on its blood disorder treatment program.

Options Bulls Blast Pharma Stock on Lifted Clinical Hold

Options Bulls Blast Phama Stock on Lifted Clinical Hold

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Dr. Bill Sheridan - CMO Charlie Gayer - CCO Dr. Helen Thackray - Chief R&D Officer Conference Call Participants Stacy Ku - Cowen and Company Jon Wolleben - JMP Securities Chris Raymond - Piper Sandler Jessica Fye - JPMorgan Maury Raycroft - Jefferies Gena Wang - Barclays Brian Abrahams - RBC Capital Markets Serge Belanger - Needham & Company Liisa Bayko - Evercore ISI Operator Welcome to the BioCryst Second Quarter 2022 Earnings Conference Call. My name is Vanessa and I will be your operator for today's call.

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call Transcript

The FDA has lifted the partial clinical hold on the biotech's kidney disease drug.

Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

—Q2 2022 ORLADEYO net revenue of $65.2 million—

News for BioCryst Pharmaceuticals Stock (BCRX)